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CONTACT DERMATITIS
Photopatch testing with an extended series of
photoallergens: a 5-year study
JOSE´ CARLOS CARDOSO, MARIA MIGUEL CANELAS, MARGARIDA GONCxALO AND AME´RICO FIGUEIREDO
Dermatology Department, University Hospital of Coimbra, Coimbra, Portugal
Objective: We conducted a retrospective study (2003–07) evaluating the results of photopatch tests
(PPTs) performed with an extended series with the objective of determining the main photoallergens
in our region and whether they would be detected by a recently recommended baseline PPT series.
Materials and methods: 83 patients (58 females/25 males, mean age 54.8 years) were tested with
a photoallergen series, and among these, 30 were also tested with a non-steroidal anti-inflammatory
drug (NSAID) series, irradiated at D2 with 5 J/cm2 ultraviolet A (UVA).
Results: Thirty-six of 83 patients (43.3%) had at least one positive reaction, with 21 (25.3%) reacting
in the photoallergen series. The main relevant reactions were as follows: 10 to ultraviolet filters
(benzophenone-3 and benzophenone-4, 3 patients each), 7 to promethazine, and 2 to chlorproma-
zine. Twenty of 30 patients tested (70%) had a relevant positive PPT to an NSAID, 9 to piroxicam
because of systemic photosensitivity, 8 to benzydamine from a topical gel or oral solution, and 2 to
ketoprofen.
Conclusions: Our results are discordant with most recently published studies because of the parti-
cularities of the population studied and to regional prescribing habits. Therefore, apart from the
recommended baseline series of photoallergens, other substances must be tested according to regional
peculiarities.
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It is generally accepted that photoallergic contact
dermatitis is uncommon, although its exact inci-
dence is unknown (1–4). At least in part, this could
be because of the underuse of photopatch testing
as a diagnostic tool. The lack of standardization
may contribute to this as well as the fact that pho-
topatch testing stands between two areas of der-
matology subspecializations: photodermatology
and contact dermatology (1). To overcome this
issue, the European Task Force for Photopatch
Testing in 2004 proposed a consensus methodol-
ogy for Europe (1). In this paper, a baseline series
including only sunscreens and four non-steroidal
anti-inflammatory drugs (NSAIDs) was defined,
although the authors recognize that other agents
should be considered according to variations in
prescribing habits in different parts of Europe,
particularly the topical NSAIDs and other less
reported agents. It is also necessary to highlight
that the use of some allergens will decrease, while
others gain importance because of activities within
the pharmaceutical and cosmetic industries. The
use of photopatch testing should be encouraged in
order to recognize these variations, allowing the
inclusion of new substances with probable increas-
ing importance and the withdrawal of older ones
from testing series.
To understand the main photoallergens in our
region of Portugal, we retrospectively evaluated
the results of photopatch tests (PPTs) performed
during 5 years using an extended series of
photoallergens.
Patients and Methods
Between 2003 and 2007, 83 patients (58 females/25
males, mean age 54.8 years) with suspected photo-
aggravated facial dermatitis or systemic photosen-
sitivity were studied. All patients were patch tested
with the European baseline series and photopatch
tested with an extended series of photoallergens
and, when appropriate, with their own products.
Among them, 30 patients (18 females/12 males,
mean age 61.0 years) were also photopatch
tested with an NSAID series. The series of photo-
allergens included among 30 substances, 11
sunscreens, 8 salicylanilides and other antiseptics,
and 5 drugs, including 2 phenothiazines (Table 1).
Allergens were purchased from Trolab (Hermal,
Reinbeck, Germany) or Chemotechnique Diag-
nostics (Vellinge, Sweden).
The NSAID series included four oxicams [pir-
oxicam at 1% petrolatum (pet.) and tenoxicam,
meloxicam, and lornoxicam all at 5% pet.], three
arylpropionic acid derivatives (ketoprofen 1%
pet., naproxen 10% pet., and ibuprofen 5% pet.),
acetylsalicylic acid and diclofenac at 10%pet., and
nimesulide and benzydamine at 5% pet. (Table 2).
Allergens for theNSAIDserieswereobtained from
Chemotechnique Diagnostics, or pure substances
supplied by the pharmaceutical industry were
prepared at our hospital.
PPTs were performed according to the recom-
mendations of the European Task Force on pho-
topatch testing (1): briefly, allergens in Finn
Chambers1 on Scanpor (Epitest Ltd Oy, Tuu-
sula, Finland) were applied in duplicate on the
back, one set was irradiated on D2 with 5 J/cm2
ultraviolet A (Waldman 7001K, Medizintechnik,
Schwenningen, Germany), and readings were per-
formed at D2, before and 30 min after irradiation,
and at D4. Only positive reactions (þ or greater,
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grading criteria) occurring exclusively on the irra-
diated set of allergens were considered, and their
relevance was evaluated.
Results
Thirty-six of 83 patients (43.3%) had at least one
positive PPT in a total of 55 positive PPTs (6 of
them to their own products).
Twenty-one patients (25.3%) showed 28 positive
PPTs in the photoallergen series (Table 3), most
reactions with current or past relevance: 13 PPTs
in 10 patients were because of ultraviolet (UV) fil-
ters (benzophenone-3 and benzophenone-4 in 3
patients each) related to the use of sunscreens or
other cosmetics, 9 PPTs to phenothiazines occurred
in 7 patients related to the use of Fenergan1 cream
(Vito´ria Laboratories, Amadora, Portugal) (con-
taining promethazine and coumarin) and in 2
because of handling chlorpromazine pills.
Twenty-one of the 30 patients (70%) tested had
a relevant positive PPT to an NSAID (Table 4), 6
of them also with a PPT in the photoallergen series,
considered either non-relevant or with a past rele-
vance. Nine PPTs to piroxicam were because of
systemic photosensitivity and were associated, in
all patients, with positive patch tests to thiomersal
and thiosalicylic acid tested at 0.1% pet. in the
baseline series and negative PPTs to the other oxi-
cams. Photoallergic contact dermatitis from ben-
zydamine occurred in eight patients, in one with
facial, forearm, and hand dermatitis because of
regular application of a topical gel (Momen gel1,
Lepori Laboratories, Lisbon, Portugal) on his wife,
and seven patients with facial dermatitis involving
mainly the chin and lower lip because of regular
gargling with oral antiseptic and anti-inflammatory
oral solution (Tantum verde1, Lepori Laborato-
ries, Lisbon, Portugal). We observed two PPTs to
ketoprofen (one in a patient with systemic
photosensitivity from fenofibrate) and one each
to acetylsalicylic acid and diclofenac attributed to
systemic photosensitivity.
Conclusions
Contrasting with most published studies on pho-
topatch testing where UV filters are by far the
most frequent photoallergens (2–6), in our popu-
lation, drugs (phenothiazines and NSAIDs) were
responsible for 80.5% of the documented cases
of photosensitivity (29 of the 36 reactive patients),
reflecting theparticular characteristics ofourpopu-
lation and their use of drugs, some of which are
not in the market of other European countries.
PPTs to UV filters were observed in 10 patients
(12.0%of the patients tested and 27.8%of reactive
patients) and were responsible for 23.6% of the
positive PPTs, with the benzophenones at the top,
as in most recent studies; para-aminobenzoic acid
(PABA) has been largely replaced, and isopropyl
dibenzoylmethane is not used in Europe (2–7).
We stress the high reactivity to phenothiazines,
particularly to promethazine that is still widely
prescribedby familyphysicians andusedas anover-
the-counter antipruritic cream. This photosensi-
tizer was frequently found in the 90s in Europe
(4, 7), even though some PPTs could have been
phototoxic reactions because of the high concen-
tration of the test material available then (1%
pet.). Our reactions occurred with the low concen-
tration (0.1%pet.) andwere relevant, as in a recent
study from Greece (8). Because of its high photo-
toxic and photosensitizing potential, this drug
should be removed from themarket, as has already
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happened inFrancewith its analogue chlorproeth-
azine contained inNeuriplege cream (Genevrier,
Antibes, France) that was shown to be phototoxic
and photoallergic (7, 9, 10).
Concerning NSAIDs and contrasting the high
frequency of photosensitivity from topical keto-
profen observed in Spain, Belgium, and Sweden
(6, 11–14), we had only one case of photoallergic
contact dermatitis to topical ketoprofen, a product
that is seldom used in Portugal. The other positive
PPT to ketoprofen occurred in a patient with
systemic photosensitivity from fenofibrate (Cata-
lip1, Fournier, Lisbon, Portugal) with a positive
PPT to the powder of the pill and was attributed
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Promethazine 0.1% pet. 7
Benzophenone-4 (sulisobenzone) 10% pet. 3
Benzophenone-3 (oxybenzone) 10% pet. 3
6-Methylcoumarin 1% pet. 2
Chlorpromazine 0.1% pet. 2




PABA (aminobenzoic acid) 10% pet. 1
Ethylhexyl methoxycinnamate 10% pet. 1




Benzophenone-10 (mexenone) 2% pet. 1
Lichen acid mix 0.3% pet. 1
Fentichlor 1% pet. 1
Triclosan 2% pet. 1
Phenofibrate pill 5/10% pet. (Catalip1) 1
Fenergan cream1, as is 3
Anthelios1 XL cream, as is 1
Avon Illuminating Eye Color, as is 1
Total of PPTs 33
Total of reactive patients 21
PABA, para-aminobenzoic acid; pet., petrolatum; PPTs,
photopatch tests.
Table 4. Positive tests in the non-steroidal anti-inflammatory




Piroxicam 1% pet. 9
Benzydamine 5% pet. 8
Ketoprofen 1% pet. 2
Diclofenac 10% pet. 1
Acetylsalicylic acid 10% pet. 1
Fenogel1 (etofenamate) as is 1
Total of PPTs 22
Total of reactive patients 21
Pet., petrolatum; PPTs, photopatch tests.
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that share a common benzophenone structure
(15). Piroxicam, used systemically, remains the
most common NSAID inducing photosensitivity
reactions; we think that this is because of its fre-
quent use in our region and also to the high prev-
alence of contact sensitization to thiomersal and
thiosalicylic acid among our population (com-
pounds that are frequent cause of cross-reactions
with piroxicam) (16). As in previous studies, no
cross-reactions were observed with the other oxi-
cams (17). Benzydamine was frequently responsi-
ble for photoallergic contact dermatitis (eight
cases), as in Spanish studies (6), but photoallergic
contact dermatitis presented mainly as a lower lip
and chin dermatitis, which is not a usual presenta-
tion for a photosensitive reaction (18).
Bruynzeel et al. (1), as already mentioned, pro-
posed a baseline PPT series to be used in Europe
and highlighted the importance of including other
agents according to regional differences. The
results of our study underline the importance of
this recommendation: if we had used only UV
filters and the four recommended NSAIDs, we
would have missed relevant reactions in 19
patients, representing 52.8% of the patients who
had positive PPTs.
References
1. Bruynzeel D P, Ferguson J, Andersen K et al. Photopatch
testing: a consensus methodology for Europe. J Eur Acad
Dermatol Venereol 2004: 18: 679–682.
2. Bryden A M, Moseley H, Ibbotson S H et al. Photopatch
testing of 1155 patients: results of the U.K. multicentre pho-
topatch study group. Br J Dermatol 2006: 155: 737–747.
3. Darvay A,White I R, Rycroft R JG, Jones A B, Haek J LM,
McFadden J P. Photoallergic contact dermatitis is uncom-
mon. Br J Dermatol 2001: 145: 597–601.
4. Bakkum R S, Heule F. Results of photpatch testing in Rot-
terdam during a 10-year period. Br J Dermatol 2002: 146:
275–279.
5. Schauder S, Ippen H. Contact and photocontact dermatitis
to sunscreens: review of a 15-year experience and of the lit-
erature. Contact Dermatitis 1997: 37: 221–232.
6. Cuadra-Oyanguren J, Pe´rez-Ferriols A, Lecha-Carrelero M,
Gime´nez-Arnau A M, Ferna´ndez-Redondo V, Ortiz de
Frutos F J, Silvestre-Salvador J F, Serra-Baldrich E. Results
and assessment of photopatch testing in Spain: towards
a new standard set of photoallergens. Actas Dermosifiliogr
2006: 98: 96–101.
7. Leonard F, Adamski H, Bonnevalle A et al. E´tude prospec-
tive multicentrique 1991-2001 de la batterie standard des
photopatch-tests de la Socie´te´ Francxaise de Photodermato-
logie. Ann Dermatol Venereol 2005: 132: 313–320.
8. Katsarou A, Makris M, Zarafonitis G, Lagogianni E,
Gregoriou S, Kalogeromitros D. Photoallergic contact der-
matitis: the 15-year experience of a tertiary reference center
in a sunny Mediterranean city. Int J Immunopathol Pharma-
col 2008: 21: 725–727.
9. Barbaud A, Collet E, Martin S, Granel F, Trechot P,
Lambert D, Schmutz J L. Contact sensitization to chlor-
proe´thazine can induce persistent light reaction and cross-
photoreactions to other phenothiazines. Contact Dermatitis
2001: 44: 373
10. KerrA,Woods J, Ferguson J. Photocontact allergic and pho-
totoxic studies of chlorproethazine. Photodermatol Photo-
immunol Photomed 2008: 24: 11–15.
11. Diaz R -L, Gardeazabal J, Manrique P, Rato´n J, Urrutia I,
Rodrigue´z-Sasiain J, Aguirre G. Greater allergenicity of top-
ical ketoprofen in contact dermatitis confirmed by use. Con-
tact Dermatitis 2006: 54: 236–243.
12. MathieuL,MeulemanL,VanHeckeE,BlondeelB,Dezfoulian
B,ConstandtL,GoossensA.Contact andphotocontact allergy
to ketoprofen. The Belgian experience. Contact Dermatitis
2004: 50: 238–241.
13. Devleeschouwer V, Roelandts R, Garmyn M, Goossens
A. Allergic and photoallergic contact dermatitis
from ketoprofen: results of (photo) patch testing and
follow-up of 42 patients. Contact Dermatitis 2008: 58:
159–166.
14. Hindse´n M, Zimerson E, Bruze M. Photoallergic contact
dermatitis from ketoprofen in southern Sweden. Contact
Dermatitis 2006: 54: 150–157.
15. Durbize E, Vigan M, Puzenat E et al. Spectrum of cross-
photosensitization in 18 consecutive patients with contact
photoallergy to ketoprofen: associated photoallergies to
non-benzophenone-containing molecules. Contact Dermati-
tis 2003: 48: 144–149.
16. Goncxalo M, Figueiredo A, Goncxalo S. Hypersensitivity to
thimerosal. The sensitizing moiety. Contact Dermatitis 1996:
34: 201–203.
17. Serra D, Goncxalo M, Figueiredo A. Two decades of cutane-
ous adverse drug reactions from piroxicam. Contact Derma-
titis 2008: 58: 35.
18. Canelas MM, Goncxalo M, Figueiredo A. Photocontact der-












Contact Dermatitis 2009: 60: 325–329 PHOTOPATCH TESTING WITH EXTENDED SERIES 329
